Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

                               NOVAVAX, INC.
                 CONSOLIDATED STATEMENT OF OPERATIONS
          (in thousands, except per share and per share information)

                                                              Unaudited
                                                           Three-month ended
                                                         March 31,  March 31,
                                                           2009       2008
     Revenues:
         Total revenues                                     $21         458

     Operating costs and expenses:
       Research and development                           4,266       4,434
       General and administrative                         2,892       3,244

         Total operating costs and expenses               7,158       7,678

     Loss from continuing operations before interest     (7,137)     (7,220)
     Interest income, (loss), net                        (1,212)        117

     Loss from continuing operations                     (8,349)     (7,103)
     Loss from discontinued operations                        -        (652)

     Net loss                                            (8,349)     (7,755)

     Basic and diluted weighted average
       number of common shares used in
       computing basic net loss per share            68,692,455  61,280,155

     Basic and diluted net loss per share
       Loss per share from continuing operations         $(0.12)     $(0.12)
        Loss 
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... This release from ... -- or even whether -- invasive saltcedar should be controlled. The Society contends that ... and carefully weigh the impact of our decisions. , ... Lawrence, KS (PRWEB) August 24, 2009 -- Saltcedar (Tamarix spp.) is ...
... LEIDEN, The Netherlands and SEATTLE, August ... innovative products for hemostasis and,regenerative medicine, today announced the ... The financing round was led by new investor,Gilde Healthcare ... investor Index Ventures. Dirk Kersten from Gilde will join ...
... , SEATTLE, Aug. 21 Cell ... closing of its previously announced sale of $30 million of shares ... of its common stock in a registered offering to a single ... its shares of Series 2 Preferred Stock and to receive the ...
Cached Biology Technology:Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 2Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 3ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing 2ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing 3Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants 2
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... BioScience includes the following peer-reviewed articles: Molecular ... Patrick J. Tranel and David P. Horvath. , Modern ... development of herbicide-resistant crops and a better understanding of ... of tools, including genomics, could yield novel and still ...
... system response that is critical to the first stages ... an entirely different direction than most scientists had thought, ... University Medical Center. "This finding will have ... development," said Michael Gunn, M.D., an immunologist and cardiologist ...
... Christopher Fasano (Memorial Sloan-Kettering Cancer Center) and colleagues lend ... stem cells outside of the neurogenic niche. , ... Bmi-1, maintains forebrain neural stem cell self-renewal. Overexpression of ... increases stem cell self-renewal both in vitro and in ...
Cached Biology News:BioScience tip sheet, March 2009 2New origin found for a critical immune response 2
... One can operate as a Voltage Clamp, as ... Clamp in electrophysiology research applications. Performance in any ... equipment. • This amazing ... in the capabilities of Digital Signal Processing (DSP) ...
... an enhanced ChemStation for the ... 2000 and Windows XP operating ... all new 7500 ICP-MS instruments ... new ChemStation using Microsofts Windows ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Soil Nematode microRNA Microarray ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: